



Innovative Cell and Tissue Technology

Press release  
February 20, 2009  
Göteborg, Sweden

## Resolution adopted by the extraordinary general meeting of Vitrolife

For purposes of Vitrolife's offer to the shareholders of MediCult, the general meeting on 19 February 2009 resolved, in accordance with the board's proposal, to authorise the board to issue new shares, to be paid for in kind, on one or several occasions up to the next annual general meeting.

**Queries should be addressed to:**

Magnus Nilsson, CEO, phone +46 31 721 80 61

---

Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation.

The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to evaluate and maintain organs outside the body in order to select usable organs and keeping them in optimal condition while waiting for transplantation. The Stem Cell Cultivation product area works with media and instruments to enable the use and handling of stem cells for therapeutic purposes.

Vitrolife today has approximately 150 employees and its products are sold in more than 80 markets. The company is headquartered in Gothenburg, Sweden, and there are subsidiaries in USA, Australia, France and Italy. Production facilities are located in Sweden and the USA.

The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.

---

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452.  
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: [info@vitrolife.com](mailto:info@vitrolife.com). Homepage: [www.vitrolife.com](http://www.vitrolife.com).

Vitrolife is required under the Swedish Securities Market Act to publish the information in this press release. The information was submitted for publication on 20 February 2009 at 08:00 am CET.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.